GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans

Pharmacogenomics. 2009 Oct;10(10):1581-7. doi: 10.2217/pgs.09.92.

Abstract

Aims: A common, functionally significant polymorphism in GRK5 (Gln41Leu) encodes a gain-of-function enzyme that enhances desensitization of the beta(1)-adrenergic receptor. GRK5 Leu41 has been postulated to confer endogenous 'genetic beta-blockade' and contribute to an attenuated response to beta-blockers in black subjects. The effects of this GRK5 variant on sensitivity to a beta-blocker have not been studied in humans. We hypothesized that the GRK5 Gln41Leu variant contributes to interindividual variability in response to beta-blockade and to the ethnic difference in sensitivity between black and Caucasian individuals.

Materials & methods: We measured the heart rate at rest and during a graded incremental exercise in 154 healthy subjects (85 white and 69 black) before and after an oral administration of 25 mg atenolol. We determined the genotypes of GRK5 (Gln41Leu), beta(1)-adrenergic receptor (ADRB1 Ser49Gly and Arg389Gly) genotypes and plasma atenolol concentrations. The effects of genotype and covariates on sensitivity to atenolol, measured as the reduction in exercise-induced tachycardia, were determined using multiple regression analyses.

Results: The minor allele frequency of GRK5 Leu41 was 32.6% in blacks and 0% in whites. Black individuals were less sensitive to atenolol than white individuals (p < or = 0.011) but this was not explained by the GRK5 genotype. The GRK5 genotype had no effect on resting heart rate before (p = 0.61) and after adjustment for age, sex, ethnicity, atenolol concentrations, BMI and ADRB1 genotypes (p = 0.81). The decrease in heart rate after atenolol administration did not differ significantly according to the GRK5 genotype at rest or after exercise, before (all p > 0.14) and after statistical adjustment for covariates (all p > 0.17).

Conclusion: The GRK5 Gln41Leu polymorphism does not affect sensitivity to the beta(1)-adrenergic blocker, atenolol, during acute physiological adrenergic stimulation, nor does it contribute to the ethnic differences in sensitivity to atenolol among black and Caucasian individuals.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adrenergic beta-1 Receptor Antagonists*
  • Adrenergic beta-Antagonists / pharmacology*
  • Adult
  • Alleles
  • Atenolol / pharmacology
  • Black People
  • Electrocardiography
  • Female
  • G-Protein-Coupled Receptor Kinase 5 / genetics*
  • Gene Frequency
  • Genetic Variation
  • Genotype
  • Heart Rate / drug effects
  • Humans
  • Male
  • Pharmacogenetics / methods
  • Polymorphism, Genetic / genetics*
  • Receptors, Adrenergic, beta-1 / genetics*
  • Tachycardia / ethnology
  • Tachycardia / genetics
  • White People

Substances

  • Adrenergic beta-1 Receptor Antagonists
  • Adrenergic beta-Antagonists
  • Receptors, Adrenergic, beta-1
  • Atenolol
  • G-Protein-Coupled Receptor Kinase 5
  • GRK5 protein, human